Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors to Reduce Cardiovascular Inflammation and Outcomes.
about
Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors to Reduce Cardiovascular Inflammation and Outcomes.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Treatment with Proprotein Conv ...... lar Inflammation and Outcomes.
@en
type
label
Treatment with Proprotein Conv ...... lar Inflammation and Outcomes.
@en
prefLabel
Treatment with Proprotein Conv ...... lar Inflammation and Outcomes.
@en
P50
P1476
Treatment with Proprotein Conv ...... lar Inflammation and Outcomes.
@en
P2093
Franco Dallegri
P304
P356
10.2174/0929867324666170303123734
P50
P577
2017-03-03T00:00:00Z